Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100

Journal of Immunotherapy

Volumn 20, Issue 1, 1997, Pages 15-25

  Zhai, Yifan ^a   Yang, James C ^a   Spiess, Paul ^a   Nishimura, Michael I ^a   Overwijk, Willem W ^a   Roberts, Bruce ^b   Restifo, Nicholas P ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Adenovirus; B16 melanoma; Cancer vaccine; In vivo model; Vaccinia virus

Indexed keywords

CANCER VACCINE; MELANOMA ANTIGEN;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; HUMAN; IMMUNOBLOTTING; IMMUNOSTIMULATION; MELANOMA; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; VACCINE PRODUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL LINE; CLONING, MOLECULAR; GENETIC CODE; HUMANS; IMMUNOTHERAPY; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SEQUENCE HOMOLOGY, NUCLEIC ACID; TUMOR CELLS, CULTURED;

EID: 0031436612     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199701000-00002     Document Type: Article

References (27)

1. Rosenberg SA. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J 1995;1:89-101.
2. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell 1995;82:13-7.
3. Pardoll DM. Tumour antigens: a new look for the 1990s [News; comment]. Nature 1994;369:357.
4. Boon T, Coulie P, Marchand M, Weynants P, Wolfel T, Brichard V. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. In: Important Advances in Oncology, Devita VT, Hellman S, Rosenberg SA, eds. Philadelphia: J. B. Lippincott, 1994:58-69.
5. Houghton AN. Cancer antigens: immune recognition of self and altered self [Comment]. J Exp Med 1994;180:1-4.
6. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
7. Kawakami Y, Eliyahu S, Delgado, CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
8. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see Comments]. J Exp Med 1994;180:35-42.
9. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178: 489-95.
10. Robbins PF, el-Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-50.
11. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91:9461-5.
12. Wang RF, Robbins PF, Kawakami Y, Rang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261]. J Exp Med 1995;181:799-804.
13. Zhai Y, Yang JC, Kawakami Y, et al. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol 1996;156:700-10.
14. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
15. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
16. Wang M, Bronte V, Chen PW, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995; 154:4685-92.
17. Kwon BS, Kim KK, Halaban R, Pickard RT. Characterization of mouse Pmel 17 gene and silver locus. Pigment Cell Res 1994;7:394-7.
18. Kwon BS, Halaban R, Ponnazhagan S, et al. Mouse silver mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17. Nucleic Acids Res 1995;23: 154-8.
19. Kobayashi T, Urabe K, Orlow SJ, et al. The Pmel 17/silver locus protein: characterization and investigation of its melanogenic function. J Biol Chem 1994;269:29198-205.
20. Mamula MJ. Lupus autoimmunity: from peptides to particles. Immunol Rev 1995;144:301-14.
21. Mamula MJ, Craft J. The expression of self antigenic determinants: implications for tolerance and autoimmunity. Curr Opin Immunol 1994;6:882-6.
22. Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995;16: 90-8.
23. Theofilopoulos AN. The basis of autoimmunity: Part II. Genetic predisposition. Immunol Today 1995;16:150-9.
24. Mamula MJ, Lin RH, Janeway CA Jr, Hardin JA. Breaking T cell tolerance with foreign and self co-immunogens: a study of autoimmune B and T cell epitopes of cytochrome c. J Immunol 1992;149:789-95.
25. Mamula MJ. The inability to process a self-peptide allows autoreactive T cells to escape tolerance. J Exp Med 1993;177: 567-71.
26. Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994;152:1453-61.
27. Bockenstedt LK, Gee RJ, Mamula MJ. Self-peptides in the initiation of lupus autoimmunity. J Immunol 1995;154: 3516-24.